A three binding site hypothesis for the interaction of ligands with monoamine G protein-coupled receptors: Implications for combinatorial ligand design

Quantitative Structure-Activity Relationships

Volumn 18, Issue 6, 1999, Pages 561-572

  Jacoby, Edgar ^a,c   Fauchère, Jean Luc ^a   Raimbaud, Eric ^a   Ollivier, Sophie ^b   Michel, André ^a,d   Spedding, Michael ^b  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Néokimia Inc   (Canada)

Author keywords

Antagonist design; Binding modes; Combinatorial libraries; Molecular modelling; Monoamine G protein coupled receptors

Indexed keywords

ACTIVATION ANALYSIS; BINDING ENERGY; BINDING SITES; COMPLEXATION; COMPUTATIONAL CHEMISTRY; MOLECULAR MODELING; MUTAGENESIS; PROTEINS;

ANTAGONIST DESIGN; BINDING MODES; BINDING-SITES; COMBINATORIAL LIBRARY; G PROTEIN COUPLED RECEPTORS; LIGAND DESIGN; LIGAND-RECEPTOR COMPLEX; MONOAMINE G PROTEIN-COUPLED RECEPTOR; SITE FILLING; THREE DIMENSIONAL MODELLING;

LIGANDS;

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ALPHA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; MONOAMINE; PROPRANOLOL; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR;

ARTICLE; BINDING SITE; CROSS LINKING; DATA BASE; DRUG BINDING SITE; GENETIC CONSERVATION; MOLECULAR MODEL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS;

EID: 0343339895     PISSN: 09318771     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-3838(199912)18:6<561::AID-QSAR561>3.0.CO;2-V     Document Type: Article

References (67)

1. Stadel, J.M., Wilson, S. and Bergsma, DJ., Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery. Trends Pharmacol. Sci. 18, 430-437 (1997).
2. Bikker, J.A., Trumpp-Kallmeyer, S. and Humblet, C., G protein-coupled receptors: models, mutagenesis, and drug design, J. Med. Chem. 41, 2911-2927 (1998).
3. Kristiansen, K., Dahl, S. and Edvardsen, O., A database of mutants and effects of site-directed mutagenesis experiments on G protein-coupled receptors, Proteins Struct. Funct. Genet. 26, 81-94 (1996).
4. 2 dopamine receptors: mutation of a histidine residue specifically affects the binding of a subgroup of substituted benzamide drugs, J. Neurochem. 62, 1664-1669 (1994).
5. Schwartz, T.W. and Rosenkilde, M.M., Is there a 'lock' for all agonist 'keys' in 7TM receptors, Trends Pharmacol. Sci. 17, 213-215 (1996).
6. Strange, P., 7TM receptors: 'locks' for 'keys'?, Trends Pharmacol. Sci. 17, 346-346 (1996).
7. Schwartz, T.W. and Rosenkilde, M.M., Schwartz and Rosenkilde reply: dogmas versus data in 7TM 'locks' for 'keys', Trends Pharmacol. Sci. 17, 347 (1996).
8. Colquhoun, D., Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors, Br. J. Pharmacol. 125, 924-947 (1998).
9. Schwartz, T.W., Locating ligand-binding sites in 7TM receptors by protein engineering, Curr. Opin. Biotechnol. 5, 434-444 (1994).
10. Spedding, M. and Dacquet, C., Transduction is a major factor influencing receptor characterization, Ann. New York Acad. Sci. 812, 29-40 (1996).
11. Spedding, M., New drug binding sites in Ca+2 channels, Trends Pharmacol Sci. 16, 139-142 (1995).
12. Spedding, M. and Paoletti, R., Classification of calcium channels and the sites of action of drugs modifying channel function, Pharmacol. Rev. 44, 363-376 (1992).
13. Grigorieff, N., Ceska, T., Downing, K., Baldwin, J. and Henderson, R., Electron-crystallographic structure of bacteriorhodopsin, J. Mol. Biol. 259, 393-421 (1996).
14. Röper, D., Krüger, P., Grötzinger, J., Wollmer, A. and Straßburger, W., Models of G protein-coupled receptors revised for family-wide compliance with experimental data. A new sequence accommodation suggested for helix G, Recept. Channel. 3, 97-106 (1995).
15. Vriend, G., WHAT IF: a molecular modeling and drug design program, J. Mol. Graph. 8, 52-56 (1990).
16. Jacoby E., Boudon, A., Kucharczyk, N., Michel, A. and Fauchère, J.-L., A structural rationale for the design of water soluble peptide derived neurokinin-1 antagonists, J. Recept. Signal Transduct. Res. 17, 855-873 (1997).
17. Horn, F., Weare, J., Beukers, M.W., Hörsch, S., Bairoch, A., Chen, W., Edvardsen, O., Champagne, F. and Vriend, G., GPCRDB: an information system for G protein-coupled receptors. Nucleic Acids Res. 26, 275-279 (1998).
18. Oliveira, L., Paiva, A.C.M. and Vriend, G., A common motif in G protein-coupled seven transmembrane helix receptors, J. Comput.-Aid Mol. Design 7, 649-658 (1993).
19. Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F. and Higgins, D.G., The Clusta1X windows interface: flexible strategies for multiple sequence alignments aided by quality analysis tools. Nucleic Acids Res. 25, 4876-4882 (1997).
20. Brancheck, T., Site-directed mutagenesis of serotonin receptors, Med. Chem. Res. 3, 287-296 (1993).
21. 1A receptor: agonist and antagonist binding sites. Drug Des. Discov. 11, 231-249 (1994).
22. Donnelly, D., Findlay, J.B.C. and Blundell, T.L., The evolution and structure of aminergic G protein-coupled receptors, Recept. Channel. 2, 61-78 (1994).
23. 2 receptor and its testing by docking of agonists and tricyclic antagonists, J. Med. Chem. 37, 2874-2888 (1994).
24. A receptors, Mol. Pharmacol. 41, 695-698 (1992).
25. A receptor, Mol. Pharmacol. 51, 889-896 (1997).
26. A receptor ligands using a three dimensional model, in: Sanz, F., Giraldo, J. and Manout, F. (Eds.), QSAR and Molecular Modeling: Concepts, Computational Tools and Biological Applications, Prous Science Publisher, Barcelona 1995, pp. 541-544.
27. A serotonin receptor, Mol. Pharmacol. 43, 516-520 (1993).
28. 2 Antagonists: a concept for the treatment of schizophrenia, Curr. Pharma. Design. 3, 367-390 (1997).
29. Trumpp-Kallmeyer, S., Hoflack, J., Bruinvels, A. and Hibert, M., Modeling of G protein-coupled receptors-application to dopamine, serotonin, acetylcholine and mammalian opsin receptors, J. Med. Chem. 35, 3448-3462 (1992).
30. Vernier, P., Cardinaud, B., Valdenaire, O., Philippe, H. and Vincent, J.-D., An evolutionary view of drug-receptor interaction: the bioamine receptor family, Trends Pharmacol. Sci. 16, 375-381 (1995).
31. Moreels, H., Lewi, P. and Janssen, P.A.J., Identification of the second extracellular loop in G protein-coupled neurotransmitter receptors as the site for ligand recognition, using spectral map analysis, in: Wouters, F.A. (Ed.), Proceedings, XIVth International Symposium on Medicinal Chemistry, 1997, pp. 355-370.
32. Kuipers, W., Oliveira, L., Vriend, G. and Ijzerman, A.P., Identification of classdetermining residues in G protein-coupled receptors by sequence analysis, Recept. Channel. 5, 159-174 (1997).
33. Van Rhee, A.M. and Jacobson, K.A., Molecular architecture of G protein-coupled receptors, Drug Develop. Res. 37, 1-38 (1996).
34. Herzyk, P. and Hubbard, R.E., Automated method for modeling seven-helix transmembrane receptors from experimental data. Biophys. J. 69, 2419-2442 (1995).
35. Baldwin, J.M., Schertler, G.F.X. and Unger, V.M., An alpha-carbon template for the transmembrane helices in the rhodopsin family of G protein-coupled receptors, J. Mol. Biol. 272, 144-164 (1997).
36. 1-adrenergic receptor subtype-selective antagonist binding, Mol. Pharmacol. 50, 1118-1126 (1996).
37. Cascieri, M.A., Fong, T.M. and Strader, C.D., Identification of critical functional groups within binding pockets of G protein-coupled receptors. Drugs of Future 21, 521-527 (1996).
38. Lewel, X.Q., A model of the adrenergic beta-2 receptor and binding sites for agonists and antagonists, Drug Des. Discov. 9, 29-48 (1992).
39. 2A receptor, J. Biol. Chem. 270, 16683-16688 (1995).
40. 2-adrenergic receptors by sodium, J. Biol. Chem. 265, 21590-21595 (1990).
41. 2 dopamine receptor, Endocrine J. 2, 7-23 (1994).
42. 1A receptor, J. Pharm. Pharmacol. 49, 698-705 (1997).
43. 1-arylpiperazines, J. Med. Chem. 40, 300-312 (1997).
44. 1A receptors: modulation of sexual activity in the male rat, Neuropharmacology 37, 769-780 (1998).
45. 1A serotonin binding sites, J. Med. Chem. 32, 1921-1926 (1989).
46. 2-adrenergic receptor ligand binding pocket, Arch. Pharm. 328, 577-584 (1995).
47. 1-adrenoceptor subtype selectivity: molecular modeling and theoretical quantitative structure-affinity relationships, Bioorg. Med. Chem. 5, 809-816 (1997).
48. 2-adrenergic receptor, J. Med. Chem. 39, 4406-4420 (1996).
49. 1Dβ receptors, Eur. J. Med. Chem. 32, 59-69 (1997).
50. D receptor in ligand binding: An indirect mechanism for receptor selectivity, Mol. Pharmacol. 44, 882-885 (1993).
51. 2-adrenergic receptor that exploits the domain structure of G protein-coupled receptors, J. Med. Chem. 40, 3871-3886 (1997).
52. Kenakin, T., Protean Agonists. Keys to receptors active states, Ann. New York Acad. Sci. 812, 116-125 (1997).
53. Cramer III, R.D., Patterson, D.E. and Bunce, J.D., Comparative molecular field analysis (CoMFA): 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110, 5959-5967 (1988).
54. Gaillard, P., Carrupt, P-A., Testa, B. and Schambel, P., Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridinylindoles to the 5-HT receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-activity relationship models, J. Med. Chem. 39, 126-134 (1996).
55. Kerrigan, K., Antidepressant patents: 1995-1997, Exp. Opin. Ther. Patents. 8, 439-460 (1998).
56. 2-muscarinic receptors, Recept. Channels 2, 107-119 (1994).
57. 2-adrenergic receptor increases its affinity for a family of α-receptor antagonists, J. Biol. Chem. 266, 15488-15492 (1991).
58. 3H]alniditan, Mol. Pharmacol. 50, 1567-1580 (1996).
59. Schotte, A., Janssen, P.F.M., Gommeren, W., Luyten, W.H.M.L., van Compel, P., Lesage, A.S., DeLoore, K. and Leysen, J.E., Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding, Psychopharmacology 124, 57-73 (1996).
60. Herz, J.M., Thomsen, W.J. and Yarbrough, G.G., Molecular approaches to receptors as targets for drug design, J. Recept. Signal Transduct. Res. 17, 671-776 (1997).
61. Kauvar, L.M., Higgins, D.L., Villar, H.O., Sportsman, J.R., Engqvist-Goldstein, A., Bukar, R., Bauer, K.E., Dilley, H. and Rocke, D.M., Predicting ligand binding to proteins by affinity fingerprints, Chem. Biol. 2, 107-118 (1995).
62. Bourne, H.R., How receptors talk to trimeric G proteins, Curr. Opin. Cell Biol. 9, 134-142 (1997).
63. 2-adrenergic receptor alters the orientation of its sixth membrane-spanning segment, J. Biol. Chem. 272, 18546-18549 (1997).
64. Hibert, M.F., Trumpp-Kallmeyer, S., Hoflack, J. and Bruinvels, A., This is not a G protein-coupled receptor, Trends Pharmacol. Sci. 14, 7-12 (1993).
65. Siegel, M.G., Shuker, A.J., Droste, C.A., Hahn, P.J., Jesudason, C.D., McDonnald III, J.H., Matthews, D.P., Rito, C.J. and Thorpe, A.J., The use of high-throughput synthesis and purification in the preparation of a direct library of adrenergic agents, Mol. Divers. 3, 113-116 (1998).
66. Drewry, D.H., Gerritz, S.W. and Linn, J.A., Solid-phase synthesis of trisubstituted guanidines, Tetrahedron. Lett. 38, 3377-3380 (1997).
67. Iwamura, T., Casey, C.T., Young, R., Dukat, M., Teitler, M., Fadden, J.S.P. and Glennon, R.A., 4-(6-Fluorobenzisoxazol-3-yl)piperidine, a risperidone metabolite with serotonergic activity of potential clinical significance, Med. Chem. Res. 6, 593-601 (1996).